TNF and inflammatory bowel disease: Growing understanding of the complex multifactorial aetiopathogenesis of IBD has led to the development and use of more targeted therapies, specifically biological agents (anti-TNF-alpha antibodies, anti-cytokine monoclonal antibodies, and anti-integrin monoclonal antibodies) to treat moderate to severe disease [5,6,7,8].